AMO Pharma has announced the initiation of REACH-CDM, a pivotal Phase 2/3 clinical trial that will assess the efficacy and safety of the investigational medication AMO-02 (tideglusib) in children and adolescents with congenital myotonic dystrophy type 1 (CDM1), also known as Steinert disease. The double-blind trial (NCT03692312) is intended to support future submissions for marketing authorization, according to AMO Pharma, which is sponsoring the study. The trial intends to enroll 56 children and adolescents with CDM1. Recruitment…

You must be logged in to read/download the full post.